How is drug resistance of cancer cells affected by ABC-transporters? A new research paper, published in the open access journal BioDiscovery, looks at the complex relationship between the second generation of tyrosine kinase ...
Mar 8, 2017
0
0
Researchers at the Stanford University School of Medicine used heart muscle cells made from stem cells to rank commonly used chemotherapy drugs based on their likelihood of causing lasting heart damage in patients.
Feb 15, 2017
0
53
In 2011, Igor Stagljar, a professor in the University of Toronto's Donnelly Centre, came across a study that genetically linked two genes in the cell to a hard-to-treat (triple negative) breast cancer. It was not clear how ...
Jan 5, 2017
0
150
(HealthDay)—Osimertinib is more effective than platinum-pemetrexed therapy in patients with T790M-positive advanced non-small-cell lung cancer whose disease has progressed during first-line epidermal growth factor receptor ...
Dec 8, 2016
0
0
Patients with a chronic type of leukaemia could safely reduce the side effects of life-long treatment by cutting their dose in half, according to the results of a University of Liverpool led study presented at an international ...
Dec 6, 2016
0
14
The "revolution in the understanding of cancer at the molecular level" has led to dramatic responses in cancer patients to new therapies that are targeted precisely at their particular type of tumours, according to an expert.
Nov 30, 2016
0
1
A high-risk subtype of acute lymphoblastic leukemia (ALL) first identified in children is highly prevalent in adults with ALL and is associated with a poor outcome, according to an international collaboration led by St. Jude ...
Nov 21, 2016
0
0
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which ...
Nov 1, 2016
0
2
Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial presented ...
Oct 11, 2016
0
0
Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North ...
Oct 3, 2016
0
6
